Navigation Links
Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
Date:9/30/2008

PHILADELPHIA In pre-clinical studies, vitamin C appears to substantially reduce the effectiveness of anticancer drugs, say researchers at Memorial Sloan-Kettering Cancer Center.

These new findings, published in the October 1 issue of Cancer Research, a publication of the American Association of Cancer Research (AACR), came from studying laboratory cancer cells and mice, but the study's authors say the same mechanism may affect patient outcomes, although they add this premise needs to be tested.

"The use of vitamin C supplements could have the potential to reduce the ability of patients to respond to therapy," said Heaney, an Associate Attending Physician at Memorial Sloan-Kettering Cancer Center.

Use of vitamin C during cancer treatment has been controversial. Some studies have suggested that because vitamin C is an antioxidant it might be beneficial to cancer patients. But some classes of chemotherapy drugs produce "oxygen free radicals," unpaired oxygen molecules that can fatally react with other molecules in a cell, forcing cell death. In this theory, vitamin C could sop up the radicals, keeping the cancer cell alive despite chemotherapy treatment.

Heaney and his colleagues tested a wide variety of chemotherapy drugs those that produce reactive oxygen and those that work in other ways on cancer cells in the laboratory, that were pretreated with dehydroascorbic acid (DHA), the form that ascorbic acid (vitamin C) takes to enter cells.

They found to their surprise that every chemotherapy drug they tested which included targeted agents like Gleevec did not work as well if cells were pretreated with vitamin C, as they did on untreated cancer cells. In the cell culture experiments, 30 to 70 percent less cancer cells treated with vitamin C were killed depending on the drug tested.

They then checked these findings by implanting the cancer cells into mice, and again found that, in an animal model sy
'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Low vitamin D during pregnancy linked to pre-eclampsia
2. Low vitamin D linked to higher risk of hip fracture
3. Vitamin E trials fatally flawed
4. Study shows vitamin C is essential for plant growth
5. Could vitamin D, a key milk nutrient, affect how you age?
6. Vitamin B-12 function may be diminished by excessive folate
7. Jefferson scientists studying the effects of high-dose vitamin C on non-Hodgkin lymphoma patients
8. New way to produce high-vitamin corn could improve nutrition in developing countries
9. Team finds an economical way to boost the vitamin A content of maize
10. Vitamin E may increase tuberculosis risk in male smokers with high vitamin C intake
11. Vitamin D and calcium influence cell death in the colon, researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
(Date:7/21/2015)... NEW YORK , July 21, 2015 /PRNewswire/ ... critical systems, as seen in the recent U.S. ... enterprises a solution to the infosec conundrum, but ... data is stored. To address this dilemma, Biometrics-as-a-Service ... of its Biometric Tokenization SDK for third party ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... and ecological sustainability of biofuels and the impact of ... America will take place on Friday, Dec. 5, in ... Neotropical Forests: Trends, Implications and Emerging Alternatives, is sponsored ... the Program in Native Species Reforestation, both joint programs ...
... Associated Professor, DSc Barbara Ann Halkier, Department of ... Life Sciences, University of Copenhagen, has been granted ... award for her excellent research into secondary metabolites, ... plants. In particular, her research has focused ...
... Company Experiences Record Revenue Growth from Operations in Third Quarter , ... bioMETRX, Inc. (OTC Bulletin Board: BMRX), a leading developer of consumer-based ... ending September 30, 2008. , , ... 430% increase over second quarter revenues of $100,000. , ...
Cached Biology News:Conference to explore sustainability of biofuels 2The Danisco Award 2008 goes to D.Sc. Barbara Ann Halkier from Faculty of Life Sciences, Copenhagen 2bioMETRX, Inc. Highlights 3rd Quarter 2008 Financial Results 2
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry is ... with a focus on the Chinese situation. Major companies included in the propanol market ... Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides a ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Mich., July 8 GeneGo, Inc., the leading,systems biology ... GeneGo products. Unilever uses systems analysis tools for,research in ... "Unilever was one of GeneGo,s first customers in Europe, ... said Julie Bryant, GeneGo,s VP,of Business development. "Unilever is ...
... Metabolex, Inc., a,biopharmaceutical company focused on the ... treatment of metabolic diseases,announced that it has promoted ... and Robert Martin to Vice President of Project ... development in our company,in support of our expanding ...
... Md., July 7 ActiPatch(TM), the,product marketed by Bioelectronics ... and the way we heal. Recently chosen as "One ... MedicalHeadway.com,ActiPatch is fast becoming the treatment of choice for ... decision to include ActiPatch in the top 9 medical ...
Cached Biology Technology:Unilever Extends Their GeneGo MetaCore License 2Metabolex Names Zhao, Martin to Executive Posts 2BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life' 2BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life' 3BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life' 4